Semaglutide-10mg.png
Semaglutide-20mg.png
Semaglutide-30mg.png
Semaglutide-10mg.png
Semaglutide-20mg.png
Semaglutide-30mg.png
Description

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. Structural modifications (an Aib substitution and a fatty-acid side chain) confer resistance to DPP-4 degradation and binding to serum albumin, extending its half-life to allow weekly dosing.

It has been studied in extensive clinical trial programs for glycemic control in type 2 diabetes (SUSTAIN trials) and for weight reduction in adults with obesity or overweight (STEP trials). More recently it has been investigated for cardiovascular outcomes (SELECT) and other metabolic endpoints.

It is used as a reference GLP-1 receptor agonist in metabolic research.

For research purposes only. Not for human consumption.

Key researches

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial (Rubino D et al., 2021)

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials (Aroda VR et al., 2019)

Obesity, Cardiovascular Disease, and the Promising Role of Semaglutide: Insights from the SELECT Trial (Irfan H, 2024)

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide (Lau J et al., 2015)

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes (Aroda VR et al., 2019)

Semaglutide

$99.00
Choose Dosage
Out of Stock